Key result
Serum FGFBP-3 shows no link to CIMT in metabolic syndrome but inversely correlates with SBP.
Why the study?
Metabolic syndrome causes arteriosclerosis, but whether fibroblast growth factor binding protein-3 (FGFBP-3) affects arteriosclerosis by changing glucose and fat metabolism remains unknown.
Observational (n=82)
No
In patients with metabolic syndrome, serum FGFBP-3 levels do not correlate with subclinical arteriosclerosis as measured by CIMT, but are inversely associated with systolic blood pressure and diabetes.
FGFBP-3 is not supported as a CIMT biomarker in metabolic syndrome; this Level 3 cohort finding leaves open any SBP association.
Introduction: Metabolic syndrome (MetS) causes arteriosclerosis (AS). Increased carotid intima-media thickness (CIMT) manifests as early vascular changes in AS. Fibroblast growth factor binding proteins (FGBP1, 2 and 3) are chaperones that are locally activated by binding paracrine FGFs from heparan sulfate stores in the extracellular matrix. Here we investigated whether FGFBP-3 affects AS by changing the glucose and fat metabolism of MetS. We propose that FGFBP-3 could be a new therapeutic agent to prevent AS by reversing MetS pathology. Methods: Eighty-two 82 patients with MetS at University of Health Sicences Turkey, stanbul Training and Research Hospital were prospectively included in the study. Serum FGFBP-3 levels of the patients were measured. For subclinical AS, CIMT was recorded with two right and left measurements using B-mode ultrasound. Results: There was no significant correlation between FGFBP-3 and CIMT levels. A significant negative correlation was found between FGFBP-3 and systolic blood pressure (SBP) (p=0.048). The FGFBP-3 level was significantly lower in the diabetes mellitus (DM) group than in the non-diabetic group (p=0.049).
No takes yet. Share an insight, caveat, or question.
Akdağ et al. (2023) conducted an observational in Metabolic Syndrome (n=82). Serum FGFBP-3 levels was evaluated on Correlation between FGFBP-3 and CIMT levels. Serum FGFBP-3 levels showed no significant correlation with carotid intima-media thickness in patients with metabolic syndrome, but were negatively correlated with systolic blood pressure (p=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: